Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT<sub>1</sub> receptor antagonist telmisartanOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested whether the anti-obesity effect of the AT1 receptor blocker telmisartan can be transferred through gut microbiota alone, independent of the drug itself. Researchers used a fecal microbiota transfer (FMT) approach in mice fed a high-fat diet to isolate the microbiome's contribution to body weight regulation. Donor stool came from mice either treated with telmisartan or given vehicle while remaining obese, and this stool was transplanted into separate acceptor mice. Microbiota composition in the recipient mice was then analyzed using 16S rRNA gene amplicon sequencing.
Who was studied?
The study used C57BL/6N mice, a standard inbred laboratory mouse strain, rather than human subjects. Acceptor mice were placed on a high-fat diet for seven weeks before receiving fecal microbiota by oral gavage for eight weeks, continuing the high-fat diet throughout. Donor mice were themselves distinguished by prior treatment: one group received telmisartan (8 mg/kg/day) for twelve weeks and stayed lean despite the high-fat diet, while control donors were obese mice given vehicle. The abstract does not report a specific cohort size for either donors or acceptors.
What were the most important findings?
Mice receiving microbiota from telmisartan-treated, lean donors gained less weight than mice receiving microbiota from obese, vehicle-treated donors, but this difference appeared only after three weeks and was no longer present by eight weeks. Energy homeostasis, insulin sensitivity, and body composition did not differ between the two groups at the endpoint measured. Overall bacterial community structure (beta-diversity) differed significantly between the groups, even though the Firmicutes to Bacteroides ratio was unchanged. Several taxa varied in abundance between groups, including Ruminococcaceae and members of the Desulfovibrionaceae family, a group of sulfate-reducing bacteria, along with unclassified Desulfovibrionia.
What are the greatest implications of this study?
These findings suggest that telmisartan's anti-adipose effect can be partially and transiently transmitted through gut microbiota, supporting a diet-independent, microbiome-mediated mechanism for the drug's action. The shift in Desulfovibrionaceae and other sulfate-reducing or sulfur-metabolizing bacteria points to microbial sulfur handling as a potential contributor to host metabolic responses after FMT. However, the loss of the weight-gain difference by eight weeks, despite persistent compositional differences in beta-diversity, indicates that microbiota transfer alone is not sufficient to sustain the full metabolic benefit of telmisartan over time. This underscores the need for further work to identify which specific taxa or microbial functions might be therapeutically relevant and durable.